Loading…
Loading…
EUDA does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for EUDA and 80,000+ other tickers.
See exactly how EUDA's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for EUDA and 80,000+ other tickers.
EUDA Health Holdings Limited engages in the provision of non-invasive healthcare services primarily in Singapore, Malaysia, and China. It offers bioenergy cabin therapy packages; stem cell therapy services through third-party treatment centers; and holistic wellness consumer products and services. The company also provides property management services. The company was founded in 2019 and is headquartered in Singapore.
SINGAPORE, AUGUST, Aug. 26, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore-based distributor of third-party wellness and non-invasive healthcare products and services in Singapore, Malaysia and China, as well as property management services in Singapore, today announced that its subsidiary, Melana International Pte. Ltd. (“Melana”), was recognised as one of the winners of the SME100 Awards 2026 Singapore, organised by Business Media International.
SINGAPORE, July 30, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) a Singapore-based distributor of third-party provided wellness and non-invasive healthcare products and services in Asia, with a focus on Singapore, Malaysia and China, today provided important additional details of the integrated cell therapy program to be pursued under its recently announced non-binding Memorandum of Understanding (MOU) with GO POSB Organoids Pte Ltd ("GO POSB") and Shenzhen Innovation Immunotechnology Co.
SINGAPORE, July 30, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) a Singapore-based distributor of third-party provided wellness and non-invasive healthcare products and services in Asia, with a focus on Singapore, Malaysia and China, today provided important additional details of the integrated cell therapy program to be pursued under its recently announced non-binding Memorandum of Understanding (MOU) with GO POSB Organoids Pte Ltd (“GO POSB”) and Shenzhen Innovation Immunotechnology Co., Ltd. (“SIIT”).
SINGAPORE, July 28, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) a Singapore-based distributor of third-party provided wellness and non-invasive healthcare products and services in Asia, with a focus on Singapore, Malaysia and China, today announced that it has signed a Memorandum of Understanding ("MOU") with GO POSB Organoids Pte Ltd ("GO POSB") and Shenzhen Innovation Immunotechnology Co.
SINGAPORE, July 28, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) a Singapore-based distributor of third-party provided wellness and non-invasive healthcare products and services in Asia, with a focus on Singapore, Malaysia and China, today announced that it has signed a Memorandum of Understanding (“MOU”) with GO POSB Organoids Pte Ltd (“GO POSB”) and Shenzhen Innovation Immunotechnology Co., Ltd. (“SIIT”) to establish a tri-party collaboration with next-generation therapies derived from induced pluripotent stem cells (“iPSC”).